Work

A bioequivalence study of proposed bevacizumab biosimilar, MYL-1402O (A) vs EU-Avastin (B) and US-Avastin (C).

Year: 2017

Type: conference-abstract

Source: Journal of Clinical Oncology

DOI: 10.1200/jco.2017.35.15_suppl.e14034

Authors: Mark A. Socinski, Matthew Hummel, Tjerk Bosje, Andrew Shaw, Mark Shiyao Liu, Mark Baczkowski, Abhijit Barve, Mudgal Kothekar, Eduardo J. Pennella

Institutions: Florida Hospital Cancer Institute, PRA Health Sciences, Mylan (United States), Biocon (India)

Language: English

Topic: Biosimilars and Bioanalytical Methods

Subfield: Immunology

Field: Immunology and Microbiology

Domain: Life Sciences

SDG: Good health and well-being

Open Access status: closed

OpenAlex ID: W2892214336

Cites:

Cited by: 6

Related to: 10